ISRCTN11093445进行中（未招募）未知
A Phase Ib/IIb, randomised, double-blind, placebo-controlled trial to investigate the safety, tolerability and clinical activity of humanised antibody GSK1070806 in the treatment of patients with moderate-to-severe Crohn's disease
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •A patient will be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications. (see Section 7.11 for additional information)
- •2. Patients that have been diagnosed with moderate to severe Crohn’s disease for at least 3 months prior to Screening Visit 1 defined by CDAI score between 220-450
- •3. Patients are required to have endoscopic evidence of active Crohn’s disease at Baseline (screening visit 1) defined by endoscopic appearance: SES-CD excluding the narrowed component of > = 6 (or > = 4 for patients with isolated ileal disease).
- •4. AST and ALT < = 2xULN; alkaline phosphatase and bilirubin < = 1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
- •5. Male or female participants aged > = 16 years (up to 80 years)
- •Male participants:
- •6. A male participant must agree to use contraception as detailed in Appendix 5 of this protocol for at least 180 days post-dose of study medication and refrain from donating sperm during this period.
- •Female participants:
- •7. A female participant is eligible to participate if she is not pregnant or breastfeeding and not a woman of childbearing potential (WOCBP) defined as at least one of the following conditions:
- •7.1. Premenopausal female with documented hysterectomy
- •7.2. Premenopausal female with documented bilateral salpingectomy or oophorectomy
- •7.3. Postmenopausal female defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
- •7.4. Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the trial. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before trial enrolment.
- •7.5. A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 for at least 180 days post-dose of trial medication. If a hormonal method of birth control is selected from the list in Appendix 1 then participants must have been using these methods at least 28 days prior to GSK1070806 administration, or be abstinent, or utilise a condom as a method of contraception until the selected hormonal method has been in place for the 28 day period.
排除标准
- •A participant will not be eligible for inclusion in this trial if any of the following criteria apply:
- •1. Diagnosis of ulcerative or indeterminate colitis
- •Crohn’s Disease complications:
- •2. Evidence of an infected abscess by MRI or other examinations
- •3. Bowel surgery other than appendectomy within 12 weeks prior to screen and/or has planned surgery or deemed likely to need surgery for CD during the trial period
- •4. Participants with ileostomies, colostomies or rectal pouches
- •5. Participants with a bowel stricture that is fixed
- •6. Participants with evidence of short bowel syndrome
- •7. Participants requiring enteral or parenteral feeding
- •8. Deep penetrating ulcers at endoscopy thought to be at risk for perforation
- •Viral and bacterial infections:
- •9. Presence of Hepatitis B surface antigen (HBsAg), (confirmed by Hepatitis B surface antigen test – within 12 months of randomisation) core antigen (HBcAg) or surface antibody (HBsAb), positive Hepatitis C (qualitative enzyme immunoassay) test result
- •10. Known varicella, herpes zoster, or other severe viral infection within 6 weeks of randomisation
- •11. The participant has a history of tuberculosis (TB) disease or latent TB infection, in the absence of documented adequate therapy for same.
- •12. Positive screening test for TB (including T-SPOT.TB TB test), unless respiratory review confirms false positive test results
- •13. History of uncontrolled bacterial or fungal infection requiring intravenous antibiotics
- •14. Positive immunoassay for Clostridium difficile toxin and other enteric pathogens
- •Other exclusion criteria:
- •15. Cardiology assessment/co-morbidity defined as:
- •15.1. QTc > 450 msec (480msec for those with Bundle Branch Block) and/or
- •15.2. Either QTcb or QTcf, machine or manual overread, males or females. The QT correction formula used to determine exclusion and discontinuation should be the same throughout the trial and/or
- •15.3. Based on single QTc value (average of triplicate readings) of ECG obtained over a brief recording period
- •16. The participant has congenital or acquired immunodeficiency, or a history of chronic or recurrent opportunistic infections
- •17. The participant has current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or cancer in situ that has been resected)
- •18. Use of any investigational drug within 30 days prior to screening, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- •19. Participant has received live, attenuated or recombinant vaccine(s) within 2 months of randomisation or will require vaccination within 3 months of trial drug infusion
- •20. Any patients that are receiving medication(s) detailed in Section 7.11.2 of the trial protocol, will not be eligible for randomisation into the trial
研究者
相似试验
已完成
1 期
A blinded study in healthy volunteers to evaluate the safety of the test medicine and compare how the test medicine behaves when the dosage is increased, and when taken alone or alongside salbutamol (albuterol)Cystic fibrosis (CF)Nutritional, Metabolic, EndocrineCystic fibrosisISRCTN30841680F. Hoffman-La Roche Ltd.41
已完成
不适用
A Phase Ib, double-blind, randomized, placebo-controlled trial in genotype 1 HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as monotherapy and given in combination with pegylated interferon + ribavirihepatitis C10047438liver diseaseNL-OMON35874PRA International EDS30
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitisModerate to severe ulcerative colitisEUCTR2019-004090-50-ESONCOSTELLAE S.L.32
进行中（未招募）
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietTreatment of celiac diseaseMedDRA version: 20.0Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004612-97-DEDr. Falk Pharma GmbH400
招募中
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietEUCTR2020-004612-97-IEDr. Falk Pharma GmbH400